VRAAG 5B: Pain

Primaire studies

Study ID	Method	Patient characteristics	Interventions	Results	Critical appraisal of study quality

Atalay 2013 Biyik 2013	• Design: Randomized crossover trial
	• Funding/CoI: supported by Selcuk Scientific Research Project Coordinating Office Project Nr 08102027/ No competing interests
	• Setting: Konya, Turkey
	• Sample size: N=50
	• Duration: 14 weeks
		• Eligibility criteria: hemodialysis patients with neuropathic pain
		• *A priori* patient characteristics: intervention vs. control
		  o Age mean: 58.2y
		  o Male 30%
		  o Hemodialysis duration: 55.1m
			Gabapentin
			
			vs.
			
			Pregabalin
				<u>Pain</u>: CRITICAL OUTCOME
				SFMPQ Total: ($p<0.001$)
				Gabapentin: before 18.9 ± 4.3, after 9.3 ± 4.3
				Pregabalin: before 18.5 ± 3.9, after 9.8 ± 3.6
				Change in % (NS):
				Gabapentin:-8.9 +/- 4.1
				Pregabalin: -9.3 +/- 4.0
				
				SFMPQ VAS: ($p<0.001$)
				Gabapentin: before 68.8 ± 12.8, after 33.0 ± 15.6
				Pregabalin: before 67.0 ± 11.8, after 32.9 ± 12.8
				Change in % (NS):
				Gabapentin:-33.5 +/- 13.2
				Pregabalin: -36.3 +/- 12.4
				
				SFMPQ PPI: ($p<0.001$)
				Gabapentin: before 2.8 ± 0.8, after 1.4 ± 0.7
				Pregabalin: before 2.8 ± 0.8, after 1.4 ± 0.7
				Change in % (NS):
				Grabapentin:-1.3 +/- 0.8
				Pregabalin: -1.4 +/- 0.6
				
				<u>Quality of life</u>: CRITICAL OUTCOME
				PSQI: ($p<0.001$)
				Gabapentin: before 8.7 ± 4.2, after 5.9 ± 3.0
				Pregabalin: before 8.8 ± 4.6, after 6.1 ± 4.2
				
				BDI: ($p<0.001$)
				Gabapentin: before 15.1 ± 7.6, after 10.9 ± 5.9
				Pregabalin: before 13.61 ± 5.9, after 10.9 ± 5.9
				
				SF-36 physical component scale score: ($p<0.001$)
				Gabapentin: before 42.6 +/- 18.2, after 57.1+/- 18.9
				Pregabalin: before 42.7 +/- 17.9, after 57.3 +/- 17.1
				Change in % (NS):
				Gabapentin: 13.0 +/- 9.2
				Pregabalin: 16.1 +/- 11.2
				
				SF-36 mental component scale score: ($p<0.001$)
				Gabapentin: before 51.6 +/- 19.5, after 63.2 +/- 18.3
				Pregabalin: before 50.5 +/- 18.6, after 63.1 +/-
					Level of evidence: high risk of bias
					
					• Unclear allocation concealment
					• Open label study
					• No ITT analysis: 10 dropouts excluded from analysis

Study ID	Method	Patient characteristics	Interventions	Results	Critical appraisal of study quality
				15.8 Change in % (p=0.043): Gabapentin:9.6 +/- 11.2 Pregabalin: 14.6 +/- 11.6	